Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences (NASDAQ / CSE: DRUG) is hosting a Key Opinion Leader (KOL) event on September 25th, 2024, focusing on their Phase 2 BREAKTHROUGH clinical trial of BMB-101 for drug-resistant epilepsies. The event will feature renowned epilepsy experts Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will discuss unmet needs in epilepsy treatment and the potential of novel therapies.
BMB-101 is the first 5-HT2C agonist in clinical studies designed to target therapeutic pathways without receptor desensitization. The KOL event will provide insights into the evolving landscape of drug-resistant seizures and highlight the scientific innovations driving the trial design. Interested parties can register for the webcast in advance, with a replay available for those unable to attend live.
Bright Minds Biosciences (NASDAQ / CSE: DRUG) ospiterà un evento con esperti di opinione chiave (KOL) il 25 settembre 2024, incentrato sul loro trial clinico di fase 2 BREAKTHROUGH di BMB-101 per le epilessie resistenti ai farmaci. L'evento presenterà rinomati esperti di epilessia Dr. Dennis Dlugos, Dr. Joe Sullivan, e Dr. Jo Sourbron, i quali discuteranno delle necessità insoddisfatte nel trattamento dell'epilessia e del potenziale delle nuove terapie.
BMB-101 è il primo agonista 5-HT2C in studi clinici progettato per colpire vie terapeutiche senza desensibilizzazione dei recettori. L'evento KOL offrirà approfondimenti sul panorama in evoluzione delle crisi resistenti ai farmaci e metterà in evidenza le innovazioni scientifiche che guidano il design dello studio. Le parti interessate possono registrarsi in anticipo per il webcast, con una replica disponibile per coloro che non possono partecipare dal vivo.
Bright Minds Biosciences (NASDAQ / CSE: DRUG) está organizando un evento de Líderes de Opinión Clave (KOL) el 25 de septiembre de 2024, centrado en su ensayo clínico de fase 2 BREAKTHROUGH de BMB-101 para epilepsias resistentes a medicamentos. El evento contará con renombrados expertos en epilepsia, Dr. Dennis Dlugos, Dr. Joe Sullivan y Dr. Jo Sourbron, quienes discutirán las necesidades no satisfechas en el tratamiento de la epilepsia y el potencial de nuevas terapias.
BMB-101 es el primer agonista 5-HT2C en estudios clínicos diseñado para dirigirse a vías terapéuticas sin desensibilización de receptores. El evento KOL proporcionará información sobre el panorama en evolución de las crisis resistentes a medicamentos y destacará las innovaciones científicas que impulsan el diseño del ensayo. Las partes interesadas pueden registrarse con anticipación para el webcast, con una repetición disponible para aquellos que no puedan asistir en vivo.
Bright Minds Biosciences (NASDAQ / CSE: DRUG)는 2024년 9월 25일에 약물 저항성 간질을 위한 BMB-101의 2상 BREAKTHROUGH 임상 시험에 중점을 둔 주요 의견 리더(KOL) 이벤트를 개최합니다. 이 행사에는 저명한 간질 전문가인 Dr. Dennis Dlugos, Dr. Joe Sullivan, Dr. Jo Sourbron이 참석하여 간질 치료의 충족되지 않은 요구 사항과 새로운 치료법의 가능성에 대해 논의할 예정입니다.
BMB-101은 수용체 탈감작 없이 치료 경로를 표적으로 삼기 위해 설계된 첫 번째 5-HT2C 작용제입니다. KOL 이벤트에서는 약물 저항성 발작의 변화하는 환경에 대한 통찰력을 제공하고 시험 설계를 주도하는 과학적 혁신을 강조할 것입니다. 관심 있는 분들은 웹캐스트에 미리 등록할 수 있으며, 생방송에 참석할 수 없는 분들을 위해 재생이 제공됩니다.
Bright Minds Biosciences (NASDAQ / CSE: DRUG) organise un événement avec des Leaders d'Opinion Clés (KOL) le 25 septembre 2024, axé sur leur essai clinique de Phase 2 BREAKTHROUGH de BMB-101 pour les épilepsies résistantes aux médicaments. L'événement mettra en vedette des experts en épilepsie de renom Dr. Dennis Dlugos, Dr. Joe Sullivan et Dr. Jo Sourbron, qui discuteront des besoins non satisfaits dans le traitement de l'épilepsie et du potentiel des nouvelles thérapies.
BMB-101 est le premier agoniste 5-HT2C dans des études cliniques conçu pour cibler des voies thérapeutiques sans désensibilisation des récepteurs. L'événement KOL offrira des perspectives sur l'évolution du paysage des crises résistantes aux médicaments et mettra en lumière les innovations scientifiques qui guident la conception de l'essai. Les parties intéressées peuvent s'inscrire à l'avance pour le webcast, avec une rediffusion disponible pour ceux qui ne peuvent pas assister en direct.
Bright Minds Biosciences (NASDAQ / CSE: DRUG) veranstaltet am 25. September 2024 eine Veranstaltung mit Schlüssel-Meinungsführern (KOL), die sich auf ihre Phase 2 BREAKTHROUGH-Studie zu BMB-101 bei medikamentenresistenten Epilepsien konzentriert. Zu den Referenten gehören renommierte Experten für Epilepsie, Dr. Dennis Dlugos, Dr. Joe Sullivan und Dr. Jo Sourbron, die unbefriedigte Bedürfnisse in der Epilepsiebehandlung und das Potenzial neuer Therapien diskutieren werden.
BMB-101 ist der erste 5-HT2C-Agonist, der in klinischen Studien entwickelt wurde, um therapeutische Wege ohne Rezeptordesensibilisierung zu zielen. Die KOL-Veranstaltung wird Einblicke in die sich entwickelnde Landschaft von medikamentenresistenten Anfällen geben und die wissenschaftlichen Innovationen hervorheben, die das Studiendesign vorantreiben. Interessierte können sich im Voraus für das Webcast anmelden, und eine Wiederholung wird für diejenigen zur Verfügung stehen, die nicht live teilnehmen können.
- None.
- None.
- Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th.
- The event will feature Epilepsy KOLs to discuss the unmet needs for epilepsy treatment.
- BMB-101 is the first 5-HT2C agonist in clinical studies designed to exclusively target therapeutic pathways (via G-protein) without receptor desensitization.
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ / CSE: DRUG) announces the Key Opinion Leader (KOL) event with leading experts in epilepsy research and treatment. The event will include Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will provide critical insights into the evolving landscape of drug-resistant seizures and the unmet needs in epilepsy care. These thought leaders will explore the scientific innovations driving the Phase 2 BREAKTHROUGH clinical trial design announced last week and highlight the potential for novel treatments.
Featured KOL speakers
Dr. Dennis J. Dlugos, MD, MSCE, is a professor of neurology and pediatrics at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Medicine. He is the Director of the Section of Clinical Neurophysiology and the Epilepsy/Clinical Neurophysiology Fellowship. He holds the Tristram C. Colket, Jr. Endowed Chair in Pediatric Neurology.
Dr. Dlugos is a member of the American Academy of Pediatrics, the American Academy of Neurology, the American Epilepsy Society, the American Clinical Neurophysiology Society, and the Child Neurology Society. Dr. Dlugos is a frequent lecturer locally and at national medical meetings on topics related to pediatric neurology, epilepsy, and electroencephalograms. He has published papers in journals such as Neurology, Epilepsia, Archives of Neurology, Pediatric Neurology, and Journal of Child Neurology.
Dr. Joseph Sullivan, a pediatric neurologist, serves as director of the UCSF Pediatric Epilepsy Center, where he specializes in evaluating and caring for children with epilepsy, particularly refractory epilepsy (in which medications fail to control seizures). He has special interests in Dravet syndrome and PCDH19-related epilepsy (two genetic forms of the condition) as well as evaluating children for epilepsy surgery.
Dr. Sullivan is a member of the American Epilepsy Society and serves on boards for several organizations. His roles include chair of the PCDH19 Alliance's scientific advisory board, member of the Epilepsy Foundation of Northern California's board of directors, and member of the Dravet Syndrome Foundation's medical advisory board and board of directors.
Dr. Jo Sourbron, MD, PhD, MPharm, is a physician scientist with a clinical practice at the University Hospitals of Ghent (UZ Ghent, Belgium) and a postdoctoral researcher at the University of Leuven (UZ/KU Leuven, Belgium).
Dr. Sourbron has a special interest in genetic forms of epilepsy and clinical trials for drug-resistant forms of epilepsy. He has been a preclinical researcher for over a decade, focused on finding novel serotonergic (5-HT) compounds for drug-resistant epilepsies. Dr. Sourbron has explored the efficacy and safety of a variety of anti epileptic drugs including, 5-HT2 agonists like fenfluramine and lorcaserin in various animal models.
For the past five years, he has been particularly involved in research involving epilepsy with eyelid myoclonia (EEM) with prominent photic induction (Sunflower syndrome). Concomitantly, he was involved in the pilot clinical trial of fenfluramine in Sunflower syndrome patients. Finally, he participated in several other clinical trials for drug-resistant epilepsies, such as cannabidiol in the treatment of drug-resistant epileptic disorders.
IMPORTANT INFORMATION:
Registration Details:
Advance registration is required to participate in the webcast. If you cannot join live, a replay will be available. Register at Livestorm.
Q&A Instructions:
To ask a question during the live Q&A session, please submit your request through the portal below the webcast player when you register or send an email to info@brightmindsbio.com.
About BMB-101
BMB-101 is a novel scaffold 5-HT2C Gq-protein biased agonist developed using structure-based drug design. It was explicitly designed for chronic treatment of neurological disorders where tolerance and drug resistance are common issues. Biased agonism at the 5-HT2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target. BMB-101 works exclusively via the Gq-protein signaling pathway and avoids beta-arrestin activation, which is crucial to minimize the risk of receptor desensitization and tolerance development. This provides a novel mechanism, anti-epileptic drug designed to provide sustained seizure relief in hard-to-treat patient populations. In preclinical studies, BMB-101 has demonstrated efficacy in animal models of Dravet Syndrome and numerous models of generalized seizures.
In Phase 1 clinical studies, BMB-101 was given to 64 healthy volunteers in a Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and food-effects study. BMB-101 was demonstrated to be safe and well tolerated at all doses. No Serious Adverse Events (SAEs) were observed, and Adverse Events (AEs) were mild in nature and in line with on-target effects for serotonergic drugs.
An extensive target-engagement study was conducted using both fluid biomarkers (transient prolactin release) and physical biomarkers (Quantitative Electroencephalogram, qEEG). Both methods confirmed robust central target engagement. A qEEG signature typical for anti-epileptic drugs was observed, with a selective depression of EEG power at frequencies observed during epileptic seizures. Furthermore, a potentiation of frontal gamma-power was observed in this study which could indicate the potential for improved cognition.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Forward-Looking Statements
This news release contains “forward-looking information”. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include design, progress, and completion of the BREAKTHROUGH Study, future clinical development of BMB-101, and future intended use or therapeutic benefit of BMB-101 to treat refractory epilepsy disorders. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These factors include the company’s financial position and operational runway, regulatory risk to operating in the pharmaceutical industry, and inaccuracies related to the assumption made by management relating to general availability of resources required to operate the studies noted in this news release. Additional risk factors can also be found in the Company’s public filings under the Company’s SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, management’s estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contact Information
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
Phone: (414)7316422
Email: alex@brightmindsbio.com
Website: www.brightmindsbio.com
FAQ
When is Bright Minds Biosciences (DRUG) hosting their KOL event on epilepsy treatment?
What is the focus of Bright Minds Biosciences' (DRUG) Phase 2 BREAKTHROUGH clinical trial?
Who are the key speakers at Bright Minds Biosciences' (DRUG) upcoming KOL event?
What makes BMB-101 unique in Bright Minds Biosciences' (DRUG) epilepsy research?
How can investors participate in Bright Minds Biosciences' (DRUG) KOL event on September 25th, 2024?
